Since no drugs have proven successful in reducing ER stress caused by mutant matrilin-3 retention, we, therefore, sought to identify alternative compounds, with the ability of promoting mutant matrilin-3 degradation and reducing pathological ER stress, which could offer therapeutic potential for patients with EDM5. Here, MATN3 is linked to multiple epiphyseal dysplasia type 5.